Amgen
amgen.dk
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Why Amgen's 6% Dividend Raise Masks a Tougher Road Ahead
Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
Read more
Report
Amgen stock draws attention after a Phase 3 trial win
Amgen stock traded at USD 418.13 on September 28, 2026, while Q2 revenue reached USD 10.05 billion. Fair value rose from USD 371.93 to USD 388.03.
Read more
Report
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?
On September 22, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for dazodalibep in systemic Sjögren's disease. The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in syste
Read more
Report
Amgen stock last trades at USD 418.60 on September 28, 2026
Amgen stock last traded at USD 418.60 on September 28, 2026. Earlier in September, the company reported an FDA monitoring update for IMDELLTRA and positive DeLLphi-305 results.
Read more
Report
Amgen Boasts Success In Sjogren's; Shares Bound Higher
Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.
Read more
Report
Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations. The answer may surprise investors who have been watching Merck's b
Read more
Report
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
Read more
Report
AMGEN reports breach to SEC
From Amgen's filing on July 29 to the Securities and Exchange Commission: Item 1.05 Material Cybersecurity Incidents. In July 2026, Amgen Inc. (the "Company") i
Read more
Report
Show more news